BUZZ-琼斯上调目标价,Enliven股价上涨,因收购吸引力增强

路透中文
Yesterday
BUZZ-琼斯上调目标价,Enliven股价上涨,因收购吸引力增强

3月25日 - ** 药物开发商Enliven Therapeutics ELVN.O股价盘前上涨14.13%至35.55美元

** Jones Trading将目标价从35美元上调至45美元,并重申 "买入 "评级

** 券商称,默克MRK.N以67亿美元收购竞争对手Terns PharmaceuticalsTERN.O的交易 (link),意味着ELVN和TERN都可以 "瓜分自己的市场份额",增加ELVN的收购吸引力。

** TERN和ELVN都在开发治疗慢性骨髓性白血病(CML)的药物,这是一种始于骨髓并导致白血病细胞失控生长的癌症。

** 经纪公司称,ELVN的先导药物ELVN-001与Terns的药物具有不同的作用机制,最适合对早期治疗已无反应的患者。

** 称TERN的先导药物TERN-701预计将主要在早期治疗领域展开竞争

** 补充说,ELVN是一个很好的收购目标,因为大多数其他CML药物都归大型制药商所有

** 2025 年,ELVN 的跌幅超过 31%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10